Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc.

Jul 26 • 04:00PM ET

1078.63

Dollar change +14.44
Percentage change 1.36	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI VHT

Scroll to Statements

Index	NDX, S&P 500	P/E	31.86	EPS (ttm)	33.85	Insider Own	3.56%	Shs Outstand	107.60M	Perf Week	1.41%
Market Cap	118.83B	Forward P/E	22.55	EPS next Y	47.83	Insider Trans	-6.08%	Shs Float	106.24M	Perf Month	0.89%
Income	3.86B	PEG	3.22	EPS next Q	10.61	Inst Own	85.44%	Short Float	1.78%	Perf Quarter	21.10%
Sales	13.10B	P/S	9.07	EPS this Y	1.54%	Inst Trans	-0.34%	Short Ratio	4.30	Perf Half Y	13.68%
Book/sh	244.93	P/B	4.40	EPS next Y	7.56%	ROA	11.98%	Short Interest	1.89M	Perf Year	47.56%
Cash/sh	95.48	P/C	11.30	EPS next 5Y	9.90%	ROE	15.28%	52W Range	723.56 - 1106.16	Perf YTD	22.81%
Dividend Est.	-	P/FCF	29.24	EPS past 5Y	10.31%	ROI	12.99%	52W High	-2.49%	Beta	0.13
Dividend TTM	-	Quick Ratio	4.51	Sales past 5Y	19.99%	Gross Margin	83.00%	52W Low	49.07%	ATR (14)	22.57
Dividend Ex-Date	-	Current Ratio	5.27	EPS Y/Y TTM	-7.49%	Oper. Margin	30.81%	RSI (14)	58.39	Volatility	2.16% 2.15%
Employees	13450	Debt/Eq	0.10	Sales Y/Y TTM	5.90%	Profit Margin	29.45%	Recom	1.79	Target Price	1117.19
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-12.56%	Payout	0.00%	Rel Volume	0.86	Prev Close	1064.19
Sales Surprise	-2.49%	EPS Surprise	-6.11%	Sales Q/Q	-0.54%	Earnings	Aug 01 BMO	Avg Volume	439.68K	Price	1078.63
SMA20	1.45%	SMA50	4.76%	SMA200	15.98%	Trades		Volume	379,288	Change	1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$625 → $851
Sep-09-22	Upgrade	Jefferies	Underperform → Hold	$536 → $675
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$630
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$625
Jun-06-22	Initiated	Jefferies	Underperform	$536
May-23-22	Initiated	SVB Leerink	Outperform	$738

Show Previous Ratings

Jul-25-24 10:02AM	Regeneron (REGN) Earnings Expected to Grow: Should You Buy? (Zacks)
07:33AM	Trials to watch: Four biologics concluding pivotal COPD trials (Clinical Trials Arena)
02:18AM	Sanofi lifts FY guidance after strong Q2 results (Investing.com)
Jul-24-24 08:37AM	Regeneron (REGN) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-18-24 07:55AM	3 Standout Stocks to Buy for the Next Bull Market (InvestorPlace)
07:55AM	Loading…
Jul-17-24 07:55AM	Stocks to Buy: 7 Founder-Led Companies Set to Outperform (InvestorPlace)
Jul-09-24 07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-08-24 08:00AM	3 No-Brainer Stocks to Buy in July (Motley Fool)
06:00AM	3 Pharma Stocks Already Ushering in the Next Biotech Boom (InvestorPlace)
Jul-05-24 03:56PM	Swing Trading Regeneron Stock Shows How To Bob And Weave (Investor's Business Daily)
02:14PM	The 3 Best Biotech Stocks to Buy in July 2024 (InvestorPlace)
08:33AM	Dupixent addresses current gap in COPD biologics landscape (Pharmaceutical Technology)
Jul-04-24 03:45PM	7 High Priced Stocks That Would Benefit From a Stock Split (InvestorPlace)
Jul-03-24 08:55AM	Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data (Benzinga)
08:06AM	Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD (Zacks)
01:00AM	Loading…
01:00AM	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (GlobeNewswire)
01:00AM	Dupixent (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD (GlobeNewswire)
Jul-02-24 07:01PM	Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN) (GuruFocus.com)
Jul-01-24 08:57AM	Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug (Zacks)
Jun-28-24 09:27AM	What's Going On With Regeneron Pharmaceuticals Stock On Friday? (Benzinga)
07:00AM	Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (GlobeNewswire)
Jun-27-24 04:05PM	Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 (GlobeNewswire)
06:40AM	3 Biotech Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-26-24 05:30PM	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (GlobeNewswire)
05:30PM	Dupixent (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine (GlobeNewswire)
Jun-24-24 04:12AM	Pipeline Moves: Approval prospects for BioTissues diabetic foot ulcer drug up after Phase III completion (Clinical Trials Arena)
Jun-21-24 06:30AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-20-24 05:04PM	Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy? (TipRanks)
Jun-18-24 01:22PM	Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead? (Zacks)
Jun-17-24 11:53AM	Regeneron touts success with bispecific antibody in multiple myeloma trial (Clinical Trials Arena)
11:23AM	Loading…
11:23AM	EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma (Clinical Trials Arena)
Jun-16-24 06:10AM	Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma (GlobeNewswire)
Jun-14-24 07:30PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Jun-13-24 08:00AM	Why It's A New Day For COPD Patients And Regeneron, Sanofi, Verona Stocks (Investor's Business Daily)
Jun-12-24 10:35PM	REGN, CI, BSX: Which Strong Buy Healthcare Stock Is the Best Bet? (TipRanks)
04:03PM	Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club (Investor's Business Daily)
10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 02:06PM	Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion (Zacks)
07:00AM	Kevzara (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) (GlobeNewswire)
Jun-07-24 10:10AM	Stock Split Watch: 3 Growth Stocks That Could Be Next (Motley Fool)
Jun-03-24 04:22PM	Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-31-24 11:23AM	FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease (Benzinga)
01:05AM	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (GlobeNewswire)
01:05AM	Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD (GlobeNewswire)
01:00AM	Update on FDA Priority Review of Dupixent (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation (GlobeNewswire)
01:00AM	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (GlobeNewswire)
May-30-24 04:45AM	Biohaven doses first subject in Phase I/II tumour treatment study (Clinical Trials Arena)
May-29-24 07:15AM	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors (PR Newswire)
May-27-24 03:02AM	The Biggest Biotechnology Company in Europe (Insider Monkey)
May-25-24 11:15PM	The Biggest Publicly Traded Biotech Company (Insider Monkey)
11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
10:00AM	2 Biotech Stocks to Buy in May (Motley Fool)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
09:28AM	Regeneron (REGN) Announces Positive Data on Oncology Candidate (Zacks)
May-23-24 05:03PM	Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO (GlobeNewswire)
06:15AM	3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years (Motley Fool)
May-22-24 07:00AM	Regeneron faces new biosimilar threats; an AI biotech lays off staff (BioPharma Dive)
May-20-24 03:33PM	Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate (MT Newswires)
02:49PM	Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 (MT Newswires)
02:15PM	Press Release: Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (GlobeNewswire)
02:15PM	Dupixent (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine (GlobeNewswire)
01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
07:38AM	Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 (MT Newswires)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-17-24 06:01PM	Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing (MT Newswires)
04:23PM	More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 (PR Newswire)
02:39PM	Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 (MT Newswires)
May-16-24 03:54PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) (Business Wire)
07:15AM	These 2 No-Brainer Growth Stocks Are Breaking New Ground (Motley Fool)
03:35AM	Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing (MT Newswires)
May-13-24 11:02AM	Dupixent set for FDA review in adolescent chronic inflammatory sinus disease (Pharmaceutical Technology)
04:41AM	Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review (MT Newswires)
04:01AM	Pipeline Moves: Phase III completion for Corcepts relaorilant (Clinical Trials Arena)
01:00AM	Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) (GlobeNewswire)
May-09-24 11:53PM	Q1 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:51AM	Regenerons gene therapy triumphs twice, restoring hearing in children (Clinical Trials Arena)
May-08-24 07:30AM	Regeneron gene therapy improves hearing in two children (BioPharma Dive)
06:07AM	Regeneron's experimental gene therapy improves hearing in one patient (Reuters)
06:00AM	Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks (GlobeNewswire)
May-07-24 10:45AM	UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating (MT Newswires)
May-06-24 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
May-05-24 08:46PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 10:20AM	Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept (MT Newswires)
10:15AM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:56AM	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 (MT Newswires)
06:15AM	Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar (InvestorPlace)
03:10AM	Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
01:08AM	Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight (GuruFocus.com)
May-02-24 04:03PM	Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms (Investor's Business Daily)
02:51PM	Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 (MT Newswires)
01:54PM	Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 (MT Newswires)
01:52PM	RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189 (MT Newswires)
10:53AM	REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:01AM	Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales (Zacks)
09:30AM	Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:32AM	Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ... (GuruFocus.com)
07:15AM	3 Biotech Stocks to Buy and Hold Through 2030 and Beyond (Motley Fool)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAROSA JOSEPH J	EVP General Counsel and Secret	Jul 11 '24	Sale	1088.95	1,866	2,031,981	37,937	Jul 12 04:00 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Jul 02 04:01 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Sale	1047.11	1,137	1,190,564	12,931	Jul 02 04:01 PM
RYAN ARTHUR F	Director	Jul 01 '24	Sale	1059.24	100	105,924	17,882	Jul 02 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jun 24 '24	Option Exercise	555.67	14,450	8,029,431	50,887	Jun 25 04:39 PM
Bassler Bonnie L	Director	Jun 24 '24	Option Exercise	371.40	756	280,778	2,138	Jun 25 04:41 PM
Bassler Bonnie L	Director	Jun 24 '24	Sale	1062.00	756	802,872	1,382	Jun 25 04:41 PM
BROWN MICHAEL S	Director	Jun 14 '24	Option Exercise	625.60	1,535	960,296	2,917	Jun 17 04:01 PM
BROWN MICHAEL S	Director	Jun 14 '24	Sale	1040.00	1,535	1,596,400	1,382	Jun 17 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 12 '24	Sale	1015.94	16,149	16,406,406	0	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 11 '24	Sale	1015.43	9,064	9,203,823	55,134	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 06 '24	Sale	1015.02	787	798,821	64,198	Jun 10 04:03 PM
Bassler Bonnie L	Director	Jun 05 '24	Option Exercise	380.95	827	315,046	2,209	Jun 07 04:06 PM
Bassler Bonnie L	Director	Jun 05 '24	Sale	1011.00	827	836,097	1,382	Jun 07 04:06 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Option Exercise	372.46	1,138	423,859	14,069	Jun 05 04:07 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Sale	980.16	1,138	1,115,422	12,931	Jun 05 04:07 PM
RYAN ARTHUR F	Director	Jun 03 '24	Sale	994.50	100	99,450	17,982	Jun 05 04:06 PM
BROWN MICHAEL S	Director	May 28 '24	Option Exercise	625.60	1,172	733,203	2,554	May 29 04:01 PM
BROWN MICHAEL S	Director	May 28 '24	Sale	974.86	1,172	1,142,536	1,382	May 29 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 21 '24	Sale	994.90	1,865	1,855,488	34,678	May 22 04:02 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 17 '24	Sale	979.23	22,830	22,355,714	466,877	May 17 05:57 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 16 '24	Sale	972.73	50,000	48,636,545	786,383	May 17 04:06 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 15 '24	Sale	975.87	50,000	48,793,727	836,383	May 17 04:04 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 15 '24	Sale	980.34	10,941	10,725,946	397,259	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 14 '24	Sale	979.25	25,000	24,481,164	408,200	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 13 '24	Option Exercise	399.66	203,204	81,212,511	577,633	May 15 06:10 PM
SING GEORGE L	Director	May 03 '24	Option Exercise	413.33	2,000	826,660	28,349	May 06 04:20 PM
McCourt Marion	EVP Commercial	May 01 '24	Sale	889.41	250	222,352	12,931	May 03 04:02 PM
RYAN ARTHUR F	Director	May 01 '24	Sale	899.61	100	89,961	18,082	May 03 04:01 PM
McCourt Marion	EVP Commercial	Apr 01 '24	Sale	964.73	250	241,182	13,181	Apr 03 04:05 PM
RYAN ARTHUR F	Director	Apr 01 '24	Sale	962.53	100	96,253	18,182	Apr 03 04:06 PM
MURPHY ANDREW J	EVP Research	Mar 14 '24	Sale	956.47	5,783	5,531,290	48,306	Mar 15 04:01 PM
MURPHY ANDREW J	EVP Research	Mar 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Mar 15 04:01 PM
McCourt Marion	EVP Commercial	Mar 01 '24	Sale	967.50	358	346,365	13,431	Mar 05 04:01 PM
RYAN ARTHUR F	Director	Mar 01 '24	Sale	982.05	100	98,205	18,282	Mar 05 04:01 PM
SING GEORGE L	Director	Feb 26 '24	Option Exercise	413.33	1,000	413,330	26,849	Feb 28 04:04 PM
Bassler Bonnie L	Director	Feb 26 '24	Option Exercise	391.92	854	334,700	2,236	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 26 '24	Sale	992.50	1,000	992,500	26,349	Feb 28 04:04 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 26 '24	Sale	990.00	1,000	990,000	36,543	Feb 28 04:04 PM
Bassler Bonnie L	Director	Feb 26 '24	Sale	979.25	854	836,280	1,382	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Option Exercise	413.33	500	206,665	26,849	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Sale	985.00	500	492,500	26,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Option Exercise	413.33	3,000	1,239,990	27,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Sale	965.00	3,000	2,895,000	26,349	Feb 26 04:07 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 22 '24	Sale	967.65	1,000	967,650	37,543	Feb 26 04:07 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Feb 15 '24	Option Exercise	399.66	172,723	69,030,474	925,209	Feb 20 04:03 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 14 '24	Sale	942.28	10,434	9,831,727	20,378	Feb 16 04:15 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 09 '24	Option Exercise	378.30	35,375	13,382,510	47,153	Feb 13 04:04 PM
SING GEORGE L	Director	Feb 09 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
Fenimore Christopher R.	SVP Finance & CFO	Feb 09 '24	Sale	953.31	4,919	4,689,320	14,372	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 09 '24	Sale	955.00	500	477,500	26,349	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 08 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 08 '24	Sale	945.00	500	472,500	26,349	Feb 12 04:02 PM
STAHL NEIL	EVP Research and Development	Feb 07 '24	Sale	950.35	8,037	7,637,954	52,019	Feb 08 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 07 '24	Sale	950.00	1,000	950,000	38,543	Feb 09 04:12 PM
McCourt Marion	EVP Commercial	Feb 05 '24	Sale	934.71	1,000	934,710	13,789	Feb 06 04:08 PM
STAHL NEIL	EVP Research and Development	Feb 02 '24	Option Exercise	399.66	30,750	12,289,545	82,769	Feb 06 04:08 PM
Landry Robert E	EVP Finance CFO	Feb 02 '24	Option Exercise	378.98	400	151,592	23,974	Feb 06 04:08 PM
McCourt Marion	EVP Commercial	Feb 01 '24	Sale	945.61	273	258,152	14,789	Feb 02 04:02 PM
RYAN ARTHUR F	Director	Feb 01 '24	Sale	954.22	100	95,422	18,382	Feb 05 04:05 PM
Landry Robert E	EVP Finance CFO	Jan 31 '24	Option Exercise	378.98	400	151,592	23,856	Feb 02 04:02 PM
Bassler Bonnie L	Director	Jan 30 '24	Option Exercise	380.95	827	315,046	2,209	Jan 31 04:52 PM
Bassler Bonnie L	Director	Jan 30 '24	Sale	959.00	827	793,093	1,382	Jan 31 04:52 PM
Landry Robert E	EVP Finance CFO	Jan 24 '24	Option Exercise	378.98	500	189,490	23,808	Jan 25 04:17 PM
Fenimore Christopher R.	SVP Controller	Jan 23 '24	Option Exercise	477.67	10,000	4,776,650	22,874	Jan 25 04:17 PM
GOLDSTEIN JOSEPH L	Director	Jan 23 '24	Option Exercise	625.60	2,707	1,693,499	9,089	Jan 25 04:18 PM
Landry Robert E	EVP Finance CFO	Jan 23 '24	Option Exercise	378.98	1,100	416,878	24,084	Jan 25 04:17 PM
GOLDSTEIN JOSEPH L	Director	Jan 23 '24	Sale	950.00	2,707	2,571,650	6,382	Jan 25 04:18 PM
Landry Robert E	EVP Finance CFO	Jan 17 '24	Option Exercise	378.98	500	189,490	23,338	Jan 18 04:02 PM
Landry Robert E	EVP Finance CFO	Jan 12 '24	Option Exercise	378.98	800	303,184	23,406	Jan 17 04:03 PM
Landry Robert E	EVP Finance CFO	Jan 04 '24	Option Exercise	378.98	500	189,490	22,948	Jan 08 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jan 03 '24	Option Exercise	399.66	34,000	13,588,440	64,036	Jan 04 04:19 PM
Fenimore Christopher R.	SVP Controller	Jan 03 '24	Option Exercise	477.67	10,000	4,776,650	20,329	Jan 04 04:22 PM
Landry Robert E	EVP Finance CFO	Jan 03 '24	Option Exercise	378.98	1,100	416,878	23,136	Jan 04 04:19 PM
Bassler Bonnie L	Director	Jan 03 '24	Option Exercise	380.95	826	314,665	2,208	Jan 04 04:11 PM
Bassler Bonnie L	Director	Jan 03 '24	Sale	914.00	826	754,964	1,382	Jan 04 04:11 PM
Zoghbi Huda Y	Director	Jan 02 '24	Option Exercise	391.92	1,117	437,775	2,364	Jan 04 04:11 PM
Landry Robert E	EVP Finance CFO	Jan 02 '24	Option Exercise	378.98	650	246,337	22,457	Jan 04 04:19 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Jan 02 '24	Sale	900.00	16,848	15,163,200	180,000	May 01 04:00 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Jan 02 '24	Sale	900.00	16,848	15,163,200	180,000	Jan 04 04:20 PM
Zoghbi Huda Y	Director	Jan 02 '24	Sale	900.00	1,117	1,005,300	1,247	Jan 04 04:11 PM
McCourt Marion	EVP Commercial	Jan 02 '24	Sale	873.91	274	239,451	15,062	Jan 04 04:17 PM
RYAN ARTHUR F	Director	Jan 02 '24	Sale	899.90	100	89,990	18,347	Jan 04 04:08 PM
Landry Robert E	EVP Finance CFO	Dec 28 '23	Option Exercise	378.98	850	322,133	22,419	Dec 29 04:05 PM
BROWN MICHAEL S	Director	Dec 27 '23	Option Exercise	482.68	2,049	989,011	3,296	Dec 29 04:06 PM
Landry Robert E	EVP Finance CFO	Dec 27 '23	Option Exercise	378.98	750	284,235	22,111	Dec 29 04:05 PM
Fenimore Christopher R.	SVP Controller	Dec 27 '23	Sale	856.71	2,448	2,097,226	14,372	Dec 29 04:04 PM
BROWN MICHAEL S	Director	Dec 27 '23	Sale	898.00	2,049	1,840,002	1,247	Dec 29 04:06 PM
Fenimore Christopher R.	SVP Controller	Dec 22 '23	Sale	846.27	250	211,568	16,820	Dec 26 04:08 PM
Fenimore Christopher R.	SVP Controller	Dec 21 '23	Sale	844.01	1,680	1,417,934	17,070	Dec 26 04:08 PM
Landry Robert E	EVP Finance CFO	Dec 13 '23	Option Exercise	378.98	1,000	378,980	22,084	Dec 14 04:08 PM
Bassler Bonnie L	Director	Dec 13 '23	Option Exercise	376.69	610	229,781	1,857	Dec 14 04:07 PM
Bassler Bonnie L	Director	Dec 13 '23	Sale	870.00	610	530,700	1,247	Dec 14 04:07 PM
McCourt Marion	EVP Commercial	Dec 11 '23	Sale	838.44	270	226,379	20,814	Dec 12 04:04 PM
MURPHY ANDREW J	EVP Research	Dec 05 '23	Sale	817.44	6,536	5,342,787	59,421	Dec 06 04:02 PM
MURPHY ANDREW J	EVP Research	Dec 04 '23	Option Exercise	270.43	20,000	5,408,600	79,421	Dec 06 04:02 PM
RYAN ARTHUR F	Director	Dec 01 '23	Sale	817.30	100	81,730	18,447	Dec 04 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 14 '23	Sale	799.17	6,492	5,188,213	59,421	Nov 15 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 13 '23	Option Exercise	270.43	20,000	5,408,600	79,421	Nov 15 04:02 PM
RYAN ARTHUR F	Director	Nov 07 '23	Sale	827.90	100	82,790	18,547	Nov 08 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc.

Upgrade your FINVIZ experience